Table 7 The result of cost-effectiveness analysis(US)
Regimen | cost ($) | Utility (QALY) | Incremental cost ($) | The incremental utility (QALY gain) | cost-utility ratio ($/QALY gain) |
|---|---|---|---|---|---|
Olaparib | 245,604.01 | 7.52 | 152,584.09 | 0.08065 | 1,891,974.19 |
The control group | 93,019.92 | 7.45 | – | – | – |